Children with craniopharyngioma resection had better response to recombinant human growth hormone therapy than those with idiopathic short stature.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
OBJECTIVE: To compare growth response and rhGH dosage requirements between children with craniopharyngioma post-resection (CP group, n=18) and those with idiopathic short stature (ISS group, n=18). METHODS: A retrospective analysis (2010-2020) was conducted on pediatric patients who received rhGH therapy. Key parameters compared between CP and ISS groups included: growth velocity (GV), rhGH dose (IU/kg/d), height, height standard deviation score (HtSDS), IGF-1 standard deviation score (IGF-1 SDS), body mass index (BMI), bone age (BA) and bone age to chronological age ratio (BA/CA). RESULTS: CP patients were older at baseline with lower HtSDS and BA/CA. Both groups had similar annual growth velocities over three years. The CP group achieved comparable height gains with half the rhGH dose of the ISS group. IGF-1 SDS increased in CP but decreased in ISS, normalizing in both. Long-term, CP patients maintained lower BA/CA and achieved higher terminal height. CONCLUSION: In this observational cohort, children with CP received approximately half the rhGH dose used in children with ISS, yet achieved comparable growth velocity and greater near-adult height.